In particular, they have reported that the pyrimidine biosynthetic enzyme dihydroorotate dehydrogenase (DHODH) consisted of a potent therapeutic target for MYCN-amplified neuroblastoma. This evidence concerns the gene DHODH and neuroblastoma.